MedTrace Logo

Palbociclib With Everolimus + Exemestane In BC

NCT02871791 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-08-29

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative.

The names of the study interventions involved in this study are:

* Palbociclib
* Everolimus
* Exemestane

Conditions

  • Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
  • Hormone Receptor (HR)-Positive Breast Cancer

Interventions

DRUG

Palbociclib

DRUG

Everolimus

DRUG

Exemestane

Sponsors & Collaborators

Principal Investigators

  • Sara Tolaney, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-24
Primary Completion
2020-12-03
Completion
2021-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02871791 on ClinicalTrials.gov